NTX-1472

Phase 2Small molecule

NNewleos Therapeutics, Inc.

NTX-1472 is one of 3 small molecule programs targeting Social Anxiety Disorder (SAD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Social Anxiety Disorder (SAD)Recruiting

Social Anxiety Disorder (SAD)Phase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Social Anxiety Disorder (SAD)

#DrugCompanyPhaseTrials

Ulotaront

IIntra-Cellular Therapies, Inc.

Approved

1 2

VQW-765

VVanda Pharmaceuticals

Phase 3

1 3

NTX-1472

NNewleos Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Social Anxiety Disorder (SAD)

NCT07323784

Clinical

Trials by Indication[1]

Social Anxiety Disorder (SAD)1 trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder

Recruiting·NNewleos Therapeutics, Inc.·Phase 2·NCT07323784·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NTX-1472. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NTX-1472 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NTX-1472. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Newleos Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNewleos Therapeutics, Inc.

NTX-1472

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Social Anxiety Disorder (SAD)1 trial

References

Drug Info

Quick Facts

Related News